Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 14803 in Chronic Hepatitis C
NCT00035945Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2001
- Primary completion
- May 2004
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of ISIS 14803 in hepatitis C (HCV), sponsored by Ionis Pharmaceuticals. Started Oct 2001; status: completed.
02
Drugs
ISIS 14803
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00035945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035945.